---
layout: default
title: Actaea Spicata Root Althaea Officinalis Root Arnic
parent: 僅模型預測 (L5)
nav_order: 149
evidence_level: L5
indication_count: 0
---

# Actaea Spicata Root Althaea Officinalis Root Arnic
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Homeopathic Formula: Repurposing Evaluation Not Feasible — Insufficient Data

## One-Sentence Summary

This Evidence Pack describes a 22-ingredient homeopathic/herbal combination product (including Arnica Montana, Black Cohosh, Hypericum Perforatum, Horse Chestnut, and Atropa Belladonna among others) whose ingredient profile is consistent with traditional rheumatic and musculoskeletal formulas.
However, the TxGNN model **generated no predicted indications** for this compound, and the drug holds **zero US market authorizations**, leaving the repurposing pathway without a computable starting point.
No clinical trial, literature, safety, or mechanistic data were retrievable for this combination as a whole.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — no market authorizations found |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no predictions, no studies) |
| US Market Status | Not marketed (0 authorizations) |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN repurposing prediction was generated for this compound, so a conventional mechanistic rationale cannot be constructed. The following observations explain why the model likely failed to produce output.

**The drug is a 22-ingredient homeopathic combination with no unified DrugBank identifier.** TxGNN operates on the Knowledge Graph (KG), which maps single chemical entities (DrugBank IDs) to disease nodes. A multi-component homeopathic formula — where each ingredient is used at dilutions that eliminate pharmacokinetic measurability — cannot be represented as a single node in the KG. As a result, neither the KG method nor the deep-learning method could generate a ranked disease prediction.

**Individual ingredients do have known pharmacological profiles**, though their relevance under homeopathic dilution is scientifically contested. Components such as Salicylic Acid (COX inhibition / anti-inflammatory), Horse Chestnut (aescin / venous tone), Hypericum Perforatum (serotonin reuptake modulation), and Atropa Belladonna (muscarinic antagonism) have established mechanisms. The overall ingredient pattern is consistent with a traditional formula targeting **musculoskeletal and rheumatic conditions** (joint pain, arthritis, soft-tissue inflammation). However, this inference is based on ingredient taxonomy alone and does not constitute a TxGNN-supported prediction.

**Proceeding with a repurposing analysis would require decomposing the formula** into individual active ingredients, mapping each to a DrugBank ID, and running separate predictions — or treating the most pharmacologically relevant single ingredient (e.g., Salicylic Acid or Hypericum Perforatum) as the anchor compound.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this combination formula.

---

## Literature Evidence

Currently no related literature available for this combination formula as a single entity.

---

## US Market Information

No US market authorizations found for this product. The formula may circulate as an OTC homeopathic product regulated under the FDA's Homeopathic Drug Products guidance rather than the standard NDA pathway, which would explain the absence of NDA records.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note on individual ingredients:** Several components carry known safety signals that would require assessment if any single-ingredient repurposing path is pursued:
> - **Atropa Belladonna** — anticholinergic toxicity risk; narrow therapeutic index
> - **Black Cohosh (Actaea spicata / Cimicifuga)** — hepatotoxicity reports in literature
> - **Hypericum Perforatum** — clinically significant CYP3A4 induction; interactions with anticoagulants, immunosuppressants, and antiretrovirals
> - **Salicylic Acid** — GI bleeding risk; contraindicated in children (Reye's syndrome)
> - **Lithium Carbonate** — narrow therapeutic index; renal and thyroid monitoring required

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline could not generate any repurposing prediction because this 22-ingredient homeopathic combination lacks a unified DrugBank ID and is not representable as a single KG node. Without a prediction, there is no evidence-based repurposing hypothesis to evaluate.

**To proceed, the following is needed:**

- **Decompose the formula:** Identify the 2–3 pharmacologically dominant ingredients (e.g., Salicylic Acid, Hypericum Perforatum, Horse Chestnut) and run individual TxGNN predictions for each
- **Assign DrugBank IDs:** Each pharmacologically active ingredient should be mapped to its DrugBank entry before re-running the KG and DL pipelines
- **Define the original indication:** Obtain the product monograph or package insert to establish the claimed therapeutic use (most likely musculoskeletal / rheumatic)
- **Clarify regulatory status:** Confirm whether the product is regulated as a homeopathic OTC, dietary supplement, or botanical drug — this determines which evidence standards apply
- **Safety review:** Commission a structured ingredient-level safety review, with particular attention to Atropa Belladonna (anticholinergic toxicity) and Hypericum Perforatum (drug interactions) before any clinical repurposing study is designed
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

